Manulife Raises Elanco Holding to 8.36 Mn Shares as Company’s 2026 Growth Story Strengthens

The Manufacturers Life Insurance Company, part of Manulife, has increased its reported position in Elanco Animal Health (NYSE: ELAN) to 8,355,772 shares, according to the latest institutional-ownership disclosures.

The development is noteworthy for the animal-health sector because it comes as Elanco is reporting stronger-than-expected 2026 operating momentum, raising its full-year outlook and accelerating deleveraging.

Not a New Position — But a Significant Increase

A review of available institutional filings shows an important distinction from some initial reports: Manulife was already an Elanco shareholder.

Its March 31, 2026 13F position was approximately 6.23 million shares. The latest reported position of 8.36 million shares therefore represents an increase of approximately 2.13 million shares, or 34.1%.

At an illustrative ELAN price of about $23.40, the 8.36-million-share position would be worth approximately $195.5 million. The precise value fluctuates with the market price and should not be interpreted as the amount Manulife paid for the shares.

MarketBeat’s latest institutional data put the position at approximately 1.67% of Elanco’s outstanding shares.

Importantly, a 13F reports holdings at a reporting date; it does not disclose the exact dates or prices at which individual shares were purchased. Therefore, the filing establishes the increase in the reported position, not necessarily that all 2.13 million additional shares were bought in one transaction.

Elanco’s Fundamentals Have Improved

The institutional increase comes against a significantly stronger operating backdrop for Elanco.

For Q2 2026, Elanco reported:

• Revenue: $1.368 billion, +10% YoY

• Organic constant-currency growth: +8%

• Reported net income: $54 million

• Adjusted net income: $174 million

• Adjusted EBITDA: $288 million, +21%

• Adjusted EBITDA margin: 21.2%

• Net leverage: 3.1× adjusted EBITDA

The company subsequently raised its FY2026 outlook to:

• Revenue: $5.09–$5.14 billion

• Adjusted EBITDA: $1.01–$1.035 billion

• Adjusted EPS: $1.10–$1.16

• Year-end net leverage target: approximately 3.0×

This represents a meaningful change from the earlier narrative around Elanco’s balance-sheet and portfolio pressures.

Companion Animal Portfolio Is Driving Momentum

Elanco’s Pet Health business generated $718 million in Q2 revenue, up 12% reported and 11% on an organic constant-currency basis.

The company highlighted strong demand for Zenrelia and Credelio Quattro. Zenrelia had reached blockbuster status on a year-to-date basis, while Credelio Quattro had penetrated more than half of the U.S. veterinary-clinic base, according to Elanco.

The Farm Animal business also grew, with Q2 revenue of $633 million, up 9% reported and 5% organically. Cattle was particularly strong, generating $313 million, up 17% reported.

That combination matters strategically: Elanco is benefiting from both companion-animal preventive healthcare and livestock productivity/disease-management demand.

Insider Buying Adds Another Signal

The Manulife position increase comes shortly after a separate insider transaction.

Elanco director Lawrence Erik Kurzius purchased 40,000 shares on August 20 at a weighted-average price of $23.398, representing approximately $935,920. Following the purchase, his direct ownership rose to 188,647 shares. The transaction was reported through an SEC Form 4.

It is reasonable for investors to view the institutional accumulation and insider purchase as positive sentiment indicators.

However, neither transaction by itself establishes that Elanco’s shares will appreciate. Institutional portfolios can reflect index, fund, mandate or portfolio-allocation decisions, while insider purchases do not guarantee future performance.

Analyst View: What Makes Elanco Interesting Now?

The more significant story is the combination of portfolio innovation + margin expansion + debt reduction. Elanco’s Q2 results showed:

Revenue growth
↓
Innovation-led market-share gains
↓
Higher margins
↓
EBITDA growth
↓
Faster deleveraging

The company reported that its Elanco Ascend productivity programme remains on track to generate $200–250 million of adjusted EBITDA net savings by 2030.

At the same time, Elanco has been increasing investment behind its innovation portfolio. The company has also announced a $25 million multi-year commitment for Elanco Ventures, targeting early-stage innovation in animal health and One Health.

What Investors Should Watch

1. Innovation revenue – Elanco raised its 2026 innovation-revenue target to $1.25 billion.

2. Debt reduction – Net leverage fell to 3.1× at June 30, compared with 3.5× at the end of Q1. Management is targeting approximately 3× by year-end.

3. Pet-health competition – Zenrelia and Credelio Quattro are becoming increasingly important growth drivers, but Elanco operates in highly competitive parasiticide, dermatology and preventive-care markets.

4. Institutional ownership – Manulife’s reported increase of approximately 34% in shares held is significant, but it should be interpreted as portfolio positioning rather than a formal endorsement of Elanco’s equity outlook.

Bottom Line

Manulife’s reported increase in its Elanco Animal Health position to 8.36 million shares is a notable institutional signal, particularly because it coincides with a materially improved operating outlook for the animal-health company.

But the most important correction is that this is not a new Manulife position: available March 31 data show approximately 6.23 million shares already held, meaning the latest position represents an estimated 2.13-million-share, 34.1% increase.

For animal-health investors, the bigger story is whether Elanco can sustain its current combination of innovation growth, margin expansion and deleveraging.

That—not institutional ownership alone—is likely to determine whether the company’s recent operational turnaround becomes a durable re-rating story.